Innovative approaches of adoptive immune cell therapy in paediatric recipients of haematopoietic stem cell transplantation

Franco Locatelli, Patrizia Comoli, Daniela Montagna, Francesca Rossi, Liane Daudt, Rita Maccario

Research output: Contribution to journalArticle

Abstract

Adoptive immune cell therapy represents one of the most promising fields of investigation in allogeneic haematopoietic stem cell transplantation (allo-HSCT). Preliminary studies indicate that adoptive immune cell therapy can be used to restore the immunocompetence of allo-HSCT recipients towards widespread pathogens in the early post-transplant period. These strategies can be of fundamental importance in patients given a T-cell-depleted allograft, a type of transplant that has been performed increasingly over the last few years. A few seminal studies have recently documented that prevention/treatment of Epstein-Barr-virus-related lymphoproliferative disorders, human cytomegalovirus disease and invasive aspergillosis can be obtained through infusion of pathogen-specific T-cell lines or clones. Several efforts are also being directed towards the identification of strategies capable of selecting and/or strengthening specific graft-vs-leukaemia responses. In this regard, strategies of ex-vivo generation and expansion of clones or cell lines, specifically or preferentially leukaemia reactive, have been developed.

Original languageEnglish
Pages (from-to)479-492
Number of pages14
JournalBest Practice and Research: Clinical Haematology
Volume17
Issue number3 SPEC.ISS.
DOIs
Publication statusPublished - Sep 2004

Fingerprint

Transplants
Pediatrics
T-cells
Hematopoietic Stem Cell Transplantation
Pathogens
Cell- and Tissue-Based Therapy
Stem cells
Graft vs Leukemia Effect
Clone Cells
T-Lymphocytes
Immunocompetence
Cell Line
Aspergillosis
Lymphoproliferative Disorders
Cytomegalovirus
Human Herpesvirus 4
Viruses
Grafts
Allografts
Leukemia

Keywords

  • Adoptive cell therapy
  • Allogeneic haematopoietic stem cell transplantation
  • DLI
  • EBV-related lymphoproliferative disorders
  • HCMV infection
  • Invasive aspergillosis
  • Leukaemia relapse
  • minimal residual disease

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Innovative approaches of adoptive immune cell therapy in paediatric recipients of haematopoietic stem cell transplantation. / Locatelli, Franco; Comoli, Patrizia; Montagna, Daniela; Rossi, Francesca; Daudt, Liane; Maccario, Rita.

In: Best Practice and Research: Clinical Haematology, Vol. 17, No. 3 SPEC.ISS., 09.2004, p. 479-492.

Research output: Contribution to journalArticle

@article{1b12e8281771452ba32a48a4829876dd,
title = "Innovative approaches of adoptive immune cell therapy in paediatric recipients of haematopoietic stem cell transplantation",
abstract = "Adoptive immune cell therapy represents one of the most promising fields of investigation in allogeneic haematopoietic stem cell transplantation (allo-HSCT). Preliminary studies indicate that adoptive immune cell therapy can be used to restore the immunocompetence of allo-HSCT recipients towards widespread pathogens in the early post-transplant period. These strategies can be of fundamental importance in patients given a T-cell-depleted allograft, a type of transplant that has been performed increasingly over the last few years. A few seminal studies have recently documented that prevention/treatment of Epstein-Barr-virus-related lymphoproliferative disorders, human cytomegalovirus disease and invasive aspergillosis can be obtained through infusion of pathogen-specific T-cell lines or clones. Several efforts are also being directed towards the identification of strategies capable of selecting and/or strengthening specific graft-vs-leukaemia responses. In this regard, strategies of ex-vivo generation and expansion of clones or cell lines, specifically or preferentially leukaemia reactive, have been developed.",
keywords = "Adoptive cell therapy, Allogeneic haematopoietic stem cell transplantation, DLI, EBV-related lymphoproliferative disorders, HCMV infection, Invasive aspergillosis, Leukaemia relapse, minimal residual disease",
author = "Franco Locatelli and Patrizia Comoli and Daniela Montagna and Francesca Rossi and Liane Daudt and Rita Maccario",
year = "2004",
month = "9",
doi = "10.1016/j.beha.2004.06.0054",
language = "English",
volume = "17",
pages = "479--492",
journal = "Best Practice and Research in Clinical Haematology",
issn = "1521-6926",
publisher = "Bailliere Tindall Ltd",
number = "3 SPEC.ISS.",

}

TY - JOUR

T1 - Innovative approaches of adoptive immune cell therapy in paediatric recipients of haematopoietic stem cell transplantation

AU - Locatelli, Franco

AU - Comoli, Patrizia

AU - Montagna, Daniela

AU - Rossi, Francesca

AU - Daudt, Liane

AU - Maccario, Rita

PY - 2004/9

Y1 - 2004/9

N2 - Adoptive immune cell therapy represents one of the most promising fields of investigation in allogeneic haematopoietic stem cell transplantation (allo-HSCT). Preliminary studies indicate that adoptive immune cell therapy can be used to restore the immunocompetence of allo-HSCT recipients towards widespread pathogens in the early post-transplant period. These strategies can be of fundamental importance in patients given a T-cell-depleted allograft, a type of transplant that has been performed increasingly over the last few years. A few seminal studies have recently documented that prevention/treatment of Epstein-Barr-virus-related lymphoproliferative disorders, human cytomegalovirus disease and invasive aspergillosis can be obtained through infusion of pathogen-specific T-cell lines or clones. Several efforts are also being directed towards the identification of strategies capable of selecting and/or strengthening specific graft-vs-leukaemia responses. In this regard, strategies of ex-vivo generation and expansion of clones or cell lines, specifically or preferentially leukaemia reactive, have been developed.

AB - Adoptive immune cell therapy represents one of the most promising fields of investigation in allogeneic haematopoietic stem cell transplantation (allo-HSCT). Preliminary studies indicate that adoptive immune cell therapy can be used to restore the immunocompetence of allo-HSCT recipients towards widespread pathogens in the early post-transplant period. These strategies can be of fundamental importance in patients given a T-cell-depleted allograft, a type of transplant that has been performed increasingly over the last few years. A few seminal studies have recently documented that prevention/treatment of Epstein-Barr-virus-related lymphoproliferative disorders, human cytomegalovirus disease and invasive aspergillosis can be obtained through infusion of pathogen-specific T-cell lines or clones. Several efforts are also being directed towards the identification of strategies capable of selecting and/or strengthening specific graft-vs-leukaemia responses. In this regard, strategies of ex-vivo generation and expansion of clones or cell lines, specifically or preferentially leukaemia reactive, have been developed.

KW - Adoptive cell therapy

KW - Allogeneic haematopoietic stem cell transplantation

KW - DLI

KW - EBV-related lymphoproliferative disorders

KW - HCMV infection

KW - Invasive aspergillosis

KW - Leukaemia relapse

KW - minimal residual disease

UR - http://www.scopus.com/inward/record.url?scp=7744245805&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7744245805&partnerID=8YFLogxK

U2 - 10.1016/j.beha.2004.06.0054

DO - 10.1016/j.beha.2004.06.0054

M3 - Article

C2 - 15498718

AN - SCOPUS:7744245805

VL - 17

SP - 479

EP - 492

JO - Best Practice and Research in Clinical Haematology

JF - Best Practice and Research in Clinical Haematology

SN - 1521-6926

IS - 3 SPEC.ISS.

ER -